Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

YI vs CANG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CANG Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–6 Matrix Metrics)

CANG Overall Winner 6-Pillar Tally: YI 2 – 3 CANG (1 Tie) Matrix Metrics: YI 6 – 4 CANG

As of Nov 19, 2026, Cango Inc. (CANG) is the stronger overall head-to-head candidate over 111, Inc. (YI) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). YI carries a Unified Composite Score of 46.0/100 (HOLD) at $2.51 (N/M Forward P/E, -0.4% operating margin), whereas CANG carries 51.3/100 (HOLD) at $1.64 (3.1x Forward P/E, -11.1% operating margin).

  • Technical & Structure Timing Caution: YI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.9); meanwhile CANG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About YI vs CANG
YI NASDAQ
111, Inc. American Depositary Shares
Retail-Drug Stores And Proprietary Stores
$2.51
-9.99% 1D
Market Cap $24.5M
TTM Revenue $10.5B
Forward P/E N/M
Beta / 30D Vol 0.50β · 40% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 48.0 Fund 47.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.2%), weak momentum, RSI 24
RSI-14: 23.9 · SMA20: $2.89 · SMA50: $3.15
CANG NYSE Head-to-Head Winner
Cango Inc. American Depositary Shares, each representing two (2) Class A Ordinary Shares
Services-Prepackaged Software
$1.64
+10.81% 1D
Market Cap $60.7M
TTM Revenue $557M
Forward P/E 3.1x
Beta / 30D Vol 8.01β · 222% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 55.0 Fund 51.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.5 · SMA20: $1.32 · SMA50: $2.08

6-Pillar Scorecard Institutional Category Breakdown (YI 2 – 3 CANG)

Columns: Metric · YI · CANG
1. Valuation Multiples CANG
Forward P/E N/M 3.1x
Trailing P/E 0.3x 3.1x
PEG Ratio N/M N/M
EV / Revenue N/M 0.2x
2. Growth & Scale YI
Revenue Growth (YoY) -28.3% -33.2%
Earnings Growth (YoY) +0.0% +137.3%
TTM Revenue (USD) $10.5B $557M
Market Cap $24.5M $60.7M
3. Profitability & Quality YI
Gross Margin 3.0% -5.4%
Operating Margin -0.4% -11.1%
Net Profit Margin -1.0% -107.2%
Return on Equity (ROE) -27.5% -151.0%
4. Balance Sheet & Cash Flow CANG
Cash Generation (TTM) -$37M EBITDA $71M EBITDA
Cash Flow Margin -0.3% EBITDA Mgn 12.7% EBITDA Mgn
Net Cash / Leverage -27.5% ROE $26M Net Debt (0.16x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CANG
OpEx & R&D Intensity 3.4% of Rev ($356M) 5.7% of Rev ($32M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Distribution Operator Capital Markets Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: YI (6) vs CANG (4)
Institutional Metric YI CANG Criterion Row Edge
Market Capitalization
Scale
$24.5M $60.7M Larger Scale CANG
Trailing P/E Ratio
Valuation
0.3x 3.1x Lower Multiple YI
Forward P/E Ratio
Valuation
N/M 3.1x Lower Multiple CANG
Revenue Growth (YoY)
Growth
-28.3% -33.2% Higher Growth YI
Operating Margin (TTM)
Profitability
-0.4% -11.1% Higher Margin YI
Net Profit Margin
Profitability
-1.0% -107.2% Higher Margin YI
Return on Equity (ROE)
Capital Efficiency
-27.5% -151.0% Higher ROE YI
52-Week Range Position
Momentum
0% ($2–$11) 37% ($0–$4) Stronger Trend CANG
Beta / 30D Volatility
Risk Regime
0.50β · 40% Vol 8.01β · 222% Vol Lower Realized Risk YI
Unified Institutional Score
Composite Signal
46.0 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite CANG
Trailing 12M Revenue (USD)
Operating Scale
$10.5B $557M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.0% -5.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$37M EBITDA (-27.5% ROE) $71M EBITDA ($26M Net Debt (0.16x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon YI +9.29 pp
YI: -20.32% · CANG: -29.61%
3M Horizon CANG +28.26 pp
YI: -27.03% · CANG: +1.23%
6M Horizon CANG +282.55 pp
YI: -57.09% · CANG: +225.46%
1Y Horizon CANG +42.13 pp
YI: -35.64% · CANG: +6.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on YI vs CANG. Trailing 12-month operating profitability (YI -0.4% vs CANG -11.1%) and valuation multiples (YI N/M vs CANG 3.1x Forward P/E) are benchmarked directly in Pillar 4 below.

YI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$10.5B
Gross Margin3.0%
Op. Margin-0.4%
ROE / Fwd P/E-27.5% · N/M
CANG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$557M
Gross Margin-5.4%
Op. Margin-11.1%
ROE / Fwd P/E-151.0% · 3.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
YI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact YI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CANG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CANG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
YI Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $24.5M market capitalization and -0.4% operating margin.
OpEx & R&D Reinvestment 3.4% of Rev ($356M)
90D Engineering Disclosures 0 Published
CANG Moat Profile Cyclical / Execution-Driven Positioning
Capital Markets Operator
Competes within the Capital Markets value chain with $60.7M market capitalization and -11.1% operating margin.
OpEx & R&D Reinvestment 5.7% of Rev ($32M)
90D Engineering Disclosures 0 Published

Investor FAQ YI vs CANG Key Questions & Quantitative Answers

As of Nov 19, 2026, Cango Inc. (CANG) is the stronger overall head-to-head candidate over 111, Inc. (YI) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). YI carries a Unified Composite Score of 46.0/100 (HOLD) at $2.51 (N/M Forward P/E, -0.4% operating margin), whereas CANG carries 51.3/100 (HOLD) at $1.64 (3.1x Forward P/E, -11.1% operating margin). Technical & Structure Timing Caution: YI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.9); meanwhile CANG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

YI leads the Growth & Scale pillar: YI posts -28.3% YoY revenue growth and +0.0% YoY earnings growth on $10.5B TTM revenue (3.0% gross margin, -0.4% operating margin), compared with CANG at -33.2% YoY revenue growth and +137.3% YoY earnings growth on $557M TTM revenue (-5.4% gross margin, -11.1% operating margin). On trailing 12-month operating scale, YI generates $10.5B in USD-normalized revenue versus $557M for CANG. In operating R&D and SG&A reinvestment, YI deploys 3.4% of Rev ($356M) (0 90-day corporate R&D disclosures) versus 5.7% of Rev ($32M) (0 disclosures) for CANG.

CANG screens cheaper on headline valuation multiples. YI trades at N/M Forward P/E, 0.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (-0.3% EBITDA margin), whereas CANG trades at 3.1x Forward P/E, 3.1x Trailing P/E, N/M PEG, and 0.2x EV/Revenue (12.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against YI (-27.5% ROE) versus CANG (-151.0% ROE) capital efficiency.

In options market volatility and institutional positioning, YI carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.50β · 40% Vol realized risk). By comparison, CANG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (8.01β · 222% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.